Evidence map›Paper›PMID 41205205›Full record

ArticleChemistry & biodiversity2026

Structure-Guided Engineering of High-Affinity Antibodies Against Zika Virus Using Deep Learning and Molecular Dynamics.

Abida Khan, Abdullah R Alzahrani, Zia Ur Rehman, Hayaa M Alhuthali, Amani A Alrehaili, Wisal A M Babiker, Saleh I Alaqel, Mohd Imran

Abstract read
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abida KhanCenter for Health Research, Northern Border University, Arar, Saudi Arabia.
Abdullah R AlzahraniDepartment of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Zia Ur RehmanHealth Research Centre, Jazan University, Jazan, Saudi Arabia.
Hayaa M AlhuthaliDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Amani A AlrehailiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Wisal A M BabikerDepartment of Public Health, Faculty of Applied Medical Science, Al-Baha University, Al-Baha, Saudi Arabia.
Saleh I AlaqelDepartment of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
Mohd ImranCenter for Health Research, Northern Border University, Arar, Saudi Arabia.ORCID https://orcid.org/0000-0002-6064-1040

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zika virus (ZIKV) remains a global health threat, for which no licensed antiviral treatment has been available. In this study, we employed in silico approaches to optimize monoclonal antibodies targeting the Zika virus envelope protein (ZIKV E) in the Domain III (DIII) region, which is crucial for receptor binding and virus entry. A high-resolution crystal structure of ZIKV E in complex with the neutralizing antibody ZV-64 was used as a template for designing a library of antibody variants through targeted double-point mutations. The variants were systematically evaluated for stability, binding affinity, solubility, and protein-protein interaction potential using FoldX, DeepPurpose, SoluProt, and molecular docking. Among all the mutants, Variants-213 and -206 were identified as the top candidates, exhibiting the most favorable predicted binding affinity and solubility compared to the control antibody. The molecular dynamics simulations further revealed the structural stability of the two mutant variants, in which Variant-206 showed a predicted binding energy (-76.90 kcal/mol) along with higher conformational flexibilities. The findings demonstrate the use of computational antibody engineering to identify potentially high-affinity therapeutics against ZIKV, providing a foundation for future experimental validation and therapeutic development against ZIKV.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralDeep LearningMolecular Dynamics SimulationProtein EngineeringZika VirusHumansMolecular Docking SimulationViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralViral Envelope Proteinsantibody stabilityenvelope proteinprotein–protein interaction (PPI)Zika virus

Identifiers

PMID41205205
PMCPMC13421850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.